Literature DB >> 29735469

Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.

Xingchi Chen1, Sainan Wang1, Lulu Lin1, Yu Li1, Hui Zhang1.   

Abstract

Atherosclerosis (AS) is a chronic inflammatory reaction with the pathological changes in the lipid deposition of arterial intima. The disorder of blood lipid metabolism is the main factor of the occurrence and development of AS, and the inflammatory reaction and autoimmune reaction also run through the development of AS. In this study, we compared the efficacy and safety of atorvastatin, simvastatin, pravastatin and rosuvastatin in the treatment of AS. At the same time, we used high resolution magnetic resonance imaging (MRI) to assess the changes in plaque area in the middle cerebral artery and the patch area before and after drug treatment. After 6 months of treatment, the number of intima-media thickness (IMT), plaque and plaque in each group were significantly lower than that before the same group. The results showed that statin treatment of AS could significantly reduce the level of blood lipids, but rosuvastatin and atorvastatin had better effects on anti inflammation and maintaining plaque stability and the drug safety was good.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29735469

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  Case Report: Advantages of High-Resolution MRI in Evaluating the Efficacy of Drug Therapy for Intracranial Atherosclerotic Plaques.

Authors:  Tao Zheng; Lei Liu; Li Li; Yang Gao; Runcai Guo; Zhi Zhou; Zunjing Liu; Kunpeng Liu
Journal:  Front Aging Neurosci       Date:  2022-04-27       Impact factor: 5.702

2.  Assessment of Therapeutic Response to Statin Therapy in Patients With Intracranial or Extracranial Carotid Atherosclerosis by Vessel Wall MRI: A Systematic Review and Updated Meta-Analysis.

Authors:  Pengyu Zhou; Yuting Wang; Jie Sun; Yannan Yu; Mahmud Mossa-Basha; Chengcheng Zhu
Journal:  Front Cardiovasc Med       Date:  2021-10-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.